Bambusa Therapeutics Presents Positive Preliminary Phase 1 BBT002 Data at American Thoracic Society 2026 (ATS 2026) International Conference and Announces First Patient Dosed in Phase 1b/2a CRSwNP Trial Written by PR Newswire Enable JavaScript and cookies to continueRead more http://www.prnasia.com/story/archive/4961389_CN61389_0